Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature

Overview of attention for article published in Frontiers in oncology, September 2024

Altmetric Badge

Mentioned by

twitter: 1 X user

So far, Altmetric has seen 1 X post from an account with 6,563 followers.

New Research: Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature https://t.co/CoKgqkRA5D #FrontiersIn #Oncology

16 Sep 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.